ArticleAtherosclerosis. Supplements2013
Differences in the atherogenic risk of patients treated by lipoprotein apheresis according to their lipid pattern.
Article in Atherosclerosis. Supplements, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 58 citations in OpenAlex.
- Clinical practice recommendations on lipoprotein apheresis for children with homozygous familial hypercholesterolemia: an expert consensus statement from ERKNet and ESPN.medRxiv : the preprint server for health sciences · 2023Article
- [State of the art: lipoprotein apheresis].Deutsche medizinische Wochenschrift (1946) · 2023Review
- Therapeutic Apheresis for Management of Lp(a) Hyperlipoproteinemia.Current atherosclerosis reports · 2020Review
- Why Some Patients Undergoing Lipoprotein Apheresis Therapy Develop New Cardiovascular Events?Journal of cardiovascular development and disease · 2020Article
- Lipoprotein(a) Lowering-From Lipoprotein Apheresis to Antisense Oligonucleotide Approach.Journal of clinical medicine · 2020Review
- Looking at Lp(a) and Related Cardiovascular Risk: from Scientific Evidence and Clinical Practice.Current atherosclerosis reports · 2019Review
- Current Role of Lipoprotein Apheresis in the Treatment of High-Risk Patients.Journal of cardiovascular development and disease · 2018Review
- Incidence of elevated lipoprotein (a) levels in a large cohort of patients with cardiovascular disease.Clinical research in cardiology supplements · 2017Article
- Hyperlipoproteinaemia(a) - apheresis and emerging therapies.Clinical research in cardiology supplements · 2017Review
- Primary and secondary prevention of cardiovascular disease in patients with hyperlipoproteinemia (a).Clinical research in cardiology supplements · 2017Review
- HyperLp(a)lipoproteinaemia: unmet need of diagnosis and treatment?Blood transfusion = Trasfusione del sangue · 2016Article
- Lipoprotein apheresis for the treatment of elevated circulating levels of lipoprotein(a): a critical literature review.Blood transfusion = Trasfusione del sangue · 2016Review
- [Therapeutic algorithm for lipoprotein apheresis and PCSK9 inhibition for severe hypercholesterolemia or isolated lipoprotein(a) hyperlipoproteinemia].Der Internist · 2016Article
- Lipoprotein apheresis in the management of severe hypercholesterolemia and of elevation of lipoprotein(a): current perspectives and patient selection.Medical devices (Auckland, N.Z.) · 2016Review
- Lipoprotein (a), an independent cardiovascular risk marker.Clinical diabetes and endocrinology · 2016Review
Corrections and comments
- Commented on by
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In high-risk patients who are already on a maximal lipid-lowering therapy, a lipoprotein apheresis is an important therapeutic option in preventing further progress of vascular complications as it may decrease both LDL-cholesterol (LDL-C) and lipoprotein(a) (Lp(a)) levels. We looked at the occurrence of cardiovascular events before apheresis and during apheresis in three groups defined by their lipid patterns at the start of an apheresis treatment: Group 1 (LDL-C ≥ 3.4 mmol/l and Lp(a) ≤ 600 mg/l; n = 35), Group 2 (LDL-C ≤ 3.4 mmol/l and Lp(a) ≥ 600 mg/l n = 37) and Group 3 (LDL-C ≥ 3.4 mmol/l and Lp(a) ≥ 600 mg/l; n = 15). Group 2 shows a time period of about 10 years from the first event until the start of apheresis treatment (compared to 2-6 years in the other two groups). Before the start of apheresis treatment 2.1 events per patient had occurred in Group 1, 3.4 events per patient in Group 2 and 1.8 events per patient in Group 3. Under apheresis therapy just 0.9 events per patient occurred in Group 1, 0.5 in Group 2 and 0.5 in Group 3. When comparing the two years before the start of apheresis treatment with the first two years under apheresis we saw the following reduction rates of cardiovascular events: Group 1-54%; Group 2-83%; Group 3-83.5%. Our results show that the reduction of cardiovascular events due to lipoprotein apheresis is especially high in patients with elevated levels of Lp(a) compared to patients with elevated LDL-C only indicating that physicians should be more focused on the risk factor elevated Lp(a).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.